Editas Medicine (EDIT) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | Barclays Maintains Equal-Weight on Editas Medicine, Lowers Price Target to $7
Benzinga14:44 ET
BofA Upgrades Editas to Buy, Cites Reni-cel Progress
Seeking Alpha14:03 ET
Express News | Editas Medicine Shares Are Trading Higher After B of A Securities Upgraded the Stock From Neutral to Buy and Raised Its Price Target From $13 to $15
BenzingaAug 8 09:24 ET
Earnings Call: Editas Medicine Optimistic Despite HHS Decision
InvestingAug 8 08:34 ET
Boot Barn To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday
BenzingaAug 8 08:13 ET
Barclays Remains a Hold on Editas Medicine (EDIT)
TipRanksAug 8 07:58 ET · Ratings

Comments

frankinglily

May 14 03:38

How does the biotech ecosystem support advancements in personalized medicine & genomics?
• Editing Genes | $CRISPR Therapeutics (CRSP.US)$ , $Intellia Therapeutics (NTLA.US)$ , $Beam Therapeutics (BEAM.US)$ , $Verve Therapeutics (VERV.US)$ , $Editas Medicine (EDIT.US)$
• Creating Therapies | $Prime Medicine (PRME.US)$ , $Sana Biotechnology (SANA.US)$
• Building DNA | $Twist Bioscience (TWST.US)$ , $Ginkgo Bioworks (DNA.US)$ , $Pacific Biosciences of California (PACB.US)$ , $Illumina (ILMN.US)$
• Dis...

7

Jaguar8

May 10 05:01

$Editas Medicine (EDIT.US)$
NEWS
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
Editas Medicine demonstrated significant scientific advances in in vivo gene editing technologies, including lipid nanoparticle formulations for efficient delivery and guide RNA modifications to enhance editing potency.
The efficacy of AsCas12a nuclease in vivo was demonstrated by Editas Medicine, sho...

1

Jaguar8

Apr 22 15:32

$Editas Medicine (EDIT.US)$
NEWS
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

1

Moomoo AI

Mar 9 06:33

Despite Editas Medicine's stock price surge, its P/S ratio remains modest due to inferior revenue forecasts. Without revenue improvement, the P/S ratio will continue to limit the share price.

Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement

Moomoo AI

Mar 2 06:23

Analysts are divided on Editas Medicine's performance, with some optimistic and others pessimistic. The projected increase in losses next year is worrisome, despite the rise in revenue estimates. The company's revenue growth is anticipated to lag behind the broader industry, posing a potential downside.

Editas Medicine, Inc. (NASDAQ:EDIT) Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates

EDIT Editas Medicine

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target